Company news
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) news
Terns Pharmaceuticals, Inc. news releases on 6ix. Latest, Feb 28, 2022: Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
Press releases — page 3
Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
February 27, 2022
Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer
January 5, 2022
Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference
January 2, 2022
Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
November 14, 2021
Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021
November 11, 2021
Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501
November 8, 2021
Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021
October 17, 2021
Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference
October 4, 2021
Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors
September 27, 2021
Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
September 7, 2021
Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
August 15, 2021
Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
June 23, 2021
Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH
June 13, 2021
Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH
June 12, 2021
Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series
May 18, 2021
Terns Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 12, 2021
Terns to Present at the 19th Annual Virtual Needham HealthCare Conference
April 6, 2021
Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021
Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH
March 21, 2021
Terns to Present on VAP-1 and FXR at NASH-TAG Conference 2021
March 7, 2021
Terns to Present at the Cowen 41st Annual Health Care Conference
February 22, 2021
Terns Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
February 9, 2021
Terns Pharmaceuticals, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock
February 3, 2021